D-Dimer post-COVID19 in Karbala governorate, Iraq

Authors

DOI:

https://doi.org/10.56294/saludcyt2024.982

Keywords:

D-dimer, COVID-19, longer-term respiratory, Period between hits, Last hit

Abstract

After the Coronavirus epidemic, there are indications that a significant number of COVID-19 survivors experience long-term respiratory, cardiovascular, and psychological issues, necessitating the assessment of these complications for effective healthcare resource allocation. The test can help identify blood clotting problems. A positive result may suggest a blood clot has recently formed and broken down. In our study, the post-covid-19 d-dimer concentration was measured, and three groups were taken for each of males and females, with a total of 30 samples. The first group are those infected once with Covid-19 and then recovered included (5) males and (5) females, and the highest concentration found in the sample (10) was 211.2 μg FEU/ml in females, it within normal limits (500 μg FEU/ml). The second group are those hits twice with Covid-19 and then recovered, it consisted from 10 samples (5 males, 5 females). The highest concentration in sample (20) was 350.62 μg FEU/ml and it has short period between hits, also was the short period between hits higher concentration from long period between hits. In the last group, those hits three times with Covid-19, then recovered, included (10) samples (5 males, 5 females), maximum concentration in sample (30) was 386.7 μg FEU/ml, it has the short period between hits. In three group was d-dimer concentration higher in females from males, and in short period between hits higher long period. The factor can increase d-dimer age, Gender, diseases, treatment, pregnancy, trauma and the vaccine to covid-19

References

1. Meisinger C, Kirchberger I, Warm TD, Hyhlik-Dürr A, Goßlau Y, Linseisen J. Elevated plasma D-dimer concentrations in adults after an outpatient-treated COVID-19 infection. Viruses. 2022;14(11):2441.

2. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American college of cardiology. 2020;75(23):2950-73.

3. Lippi G, Mullier F, Favaloro EJ. D-dimer: old dogmas, new (COVID-19) tricks. Clinical Chemistry and Laboratory Medicine (CCLM). 2023;61(5):841-50.

4. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert review of hematology. 2020;13(11):1265-75.

5. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood, The Journal of the American Society of Hematology. 2009;113(13):2878-87.

6. Tosun AI, Yarimcan F. CPQ Microbiology (2020) 5: 1 Research Article. 2020.

7. Hashem MK, Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Hassany SM, et al. Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer. The Egyptian Journal of Bronchology. 2021;15(1):29.

8. Trofin F, Nastase EV, Roșu MF, Bădescu AC, Buzilă ER, Miftode EG, et al. Inflammatory Response in COVID-19 Depending on the Severity of the Disease and the Vaccination Status. International journal of molecular sciences. 2023;24(10):8550.

9. Ornelas-Aguirre JM, Gómez-Alcalá AV, Ramírez-Leyva DH. Increment of D-dimer Associated with Immune Thrombotic Thrombocytopenia in ChAdOx1 nCoV-19 (AstraZeneca-Oxford) Vaccinated Individuals: A Systematic Review. Archives of Medical Research. 2022.

10. Lippi G, Mullier F, Favaloro EJ. D-dimer: Old dogmas, new (COVID-19) tricks. Clinical Chemistry and Laboratory Medicine (CCLM). 2022.

11. Aydin G, Golcuk E. Prolonged Elevation of D-dimer Levels In The Post-Covid-19 Period. 2023.

12. Gameil MA, Marzouk RE, Elsebaie AH, Rozaik SE. Long-term clinical and biochemical residue after COVID-19 recovery. Egyptian liver journal. 2021;11:1-8.

13. Porfidia A, Pola R. Venous thromboembolism in COVID‐19 patients. Journal of thrombosis and haemostasis. 2020;18(6):1516-7.

14. Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of thrombosis and thrombolysis. 2020;50:72-81.

15. Milenkovic B, Vukosavljevic D, Isovic L, Postic A, Cvok-Debeljak T. Characteristics of Patients With Post-COVID-19 Pulmonary Embolism. C64 EXPANDING THE VENN DIAGRAM: COVID-19 AND THE PULMONARY VASCULATURE: American Thoracic Society; 2023. p. A5556-A

Downloads

Published

2024-09-13

How to Cite

1.
Hadi Alhamdani AS, Al-Mamoori GS, Khudhair HM, Hamza Jaber FR, Albazoni HJ, Mohammedhassan AM, et al. D-Dimer post-COVID19 in Karbala governorate, Iraq. Salud, Ciencia y Tecnología [Internet]. 2024 Sep. 13 [cited 2024 Oct. 14];4:.982. Available from: https://sct.ageditor.ar/index.php/sct/article/view/982